Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Systematic Review Article

Compounds from Natural Products Candidates to Drug for Chikungunya Virus Infection: A Systematic Review

In Press, (this is not the final "Version of Record"). Available online 06 June, 2024
Author(s): Larissa de Mattos Oliveira, Janay Stefany Carneiro Araújo, Kaio Vinicius Freitas de Andrade, Ana Tereza Gomes Guerrero and Manoelito Coelho dos Santos Junior*
Published on: 06 June, 2024

DOI: 10.2174/0113894501304256240524052446

Price: $95

Abstract

Introduction: Chikungunya fever is a disease caused by infection with the Chikungunya virus, transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Despite its self-limited character, more than 60% of patients have chronic recurrent arthralgia with debilitating pain that lasts for years.

Aim: The objective of this review was to gather and analyze evidence from the literature on potential therapeutic strategies with molecules from natural products for the treatment of Chikungunya fever.

Methods: A search was performed for clinical trials, observational studies, in vitro or in vivo, without restriction of the year of publication or language in electronic databases (Medline/PubMed, EMBASE, Google Scholar, The Cochrane Library, LILACS (BVS), clinical trial registries (Clinical Trials.gov), digital libraries from CAPES theses and dissertations (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) and conference abstracts. A quality assessment of the selected studies was performed using the SYRCLE, RoB2 and SciRAP tools.

Results: 42 studies were included, which showed molecules with potential antiviral pharmacological activity or with activity in reducing the joint complications caused by CHIKV infection.

Conclusions: Among the molecules found in the survey of references, regarding the class of secondary metabolites, flavonoids stood out and for this reason, the molecules may be promising candidates for future clinical trials. Overall, evidence from in vitro studies was of acceptable quality; in vivo and intervention studies showed a high risk of bias, which is a limitation of these studies

Keywords: Chikungunya fever, Chikungunya virus, Drug Discovery, Biological Products, Secondary metabolites, Drug candidates


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy